In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Freshfields announced today that Phillip Stoup has joined as a capital markets partner in Silicon Valley.

statements about management’s expectations regarding Organon’s recent acquisition of Dermavant Sciences Ltd. (“Dermavant”) and potential regulatory approval from the FDA for the use of VTAMA® in the ...

An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug ...

Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. JP Morgan does not expect any major surprise in the Q3 earnings, with the generic version ...

Organon (NYSE:OGN) and partner Shanghai Henlius Biotech said the FDA has accepted the Biologics License Application for HLX14 ...

3,4 “The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio. With the deal's closure, Organon has added Dermavant’s VTAMA (tapinarof) ...